Nabriva Therapeutics AG (NASDAQ:NBRV) had its price target upped by equities research analysts at HC Wainwright from $18.00 to $20.00 in a research report issued to clients and investors on Wednesday. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 226.80% from the stock’s current price.

NBRV has been the subject of several other reports. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a research note on Wednesday, October 11th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a research note on Friday, September 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price (up from $15.00) on shares of Nabriva Therapeutics AG in a research note on Tuesday, September 19th. SunTrust Banks, Inc. initiated coverage on shares of Nabriva Therapeutics AG in a research note on Friday, August 25th. They set a “buy” rating and a $20.00 target price for the company. Finally, ValuEngine cut shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $19.03.

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 6.12 on Wednesday. The stock’s 50 day moving average price is $7.56 and its 200 day moving average price is $9.32. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $14.10. The firm’s market cap is $164.25 million.

Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.34 million. On average, equities analysts anticipate that Nabriva Therapeutics AG will post ($2.29) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/11/01/nabriva-therapeutics-ag-nbrv-price-target-raised-to-20-00.html.

In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 17,790 shares of Nabriva Therapeutics AG stock in a transaction on Monday, August 7th. The shares were sold at an average price of $10.50, for a total value of $186,795.00. Following the completion of the transaction, the insider now directly owns 2,373,387 shares of the company’s stock, valued at approximately $24,920,563.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the company’s stock in a transaction on Monday, September 18th. The stock was acquired at an average cost of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 57,219 shares of company stock valued at $535,919 and sold 74,840 shares valued at $714,161. Company insiders own 2.75% of the company’s stock.

Large investors have recently modified their holdings of the business. Almanack Investment Partners LLC. grew its stake in shares of Nabriva Therapeutics AG by 482.2% in the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after buying an additional 751,366 shares in the last quarter. Nationwide Fund Advisors grew its stake in shares of Nabriva Therapeutics AG by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after buying an additional 7,924 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after buying an additional 8,650 shares in the last quarter. 50.24% of the stock is owned by institutional investors and hedge funds.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.